ONSEMBLE mCRC

Clinical Programs

The CRDF-004 phase 2 randomized trial for the 1st line treatment of patients with a RAS-mutated metastatic colorectal cancer (mCRC) is designed to generate preliminary safety and efficacy data, and confirm the optimal dose

ENDPOINTS

Primary
  • Objective¬†Response Rate: CR + PR
Key Secondary
  • Duration of Response
  • Progression-Free Survival
Benchmark of Success
  • Objective Response Rate ‚Č•65%